Qiagen Stock Price, News & Analysis

QIAGEN (NYSE: QGEN) has launched the QIAprep CRISPR Kit and CRISPR Q-Primer Solutions, enhancing speed and efficiency in analyzing edited genetic material. This launch targets the booming CRISPR technology sector, crucial for gene editing and biomedical research. The new products facilitate a sensitive, all-in-one approach to analyze gene editing effects, reducing experimental time significantly. These solutions support various cell culturing methods and can be customized for targeted applications, potentially accelerating breakthroughs in areas like cancer therapy and drug development.

QIAGEN N.V. (QGEN) has launched an expanded scope of companion diagnostic claims for the therascreen KRAS RGQ PCR Kit, following FDA approval. This kit aids in identifying non-small cell lung cancer (NSCLC) patients eligible for Amgen's LUMAKRAS^TM treatment, targeting the KRAS G12C mutation, present in up to 13% of NSCLC cases. This approval marks a significant milestone in precision medicine, enhancing QIAGEN's therascreen portfolio and expanding testing availability through its Day-One Lab Readiness program.

QIAGEN N.V. announced a global collaboration with Mirati Therapeutics to develop a tissue-based KRAS companion diagnostic for cancers with the KRAS^G12C mutation, focusing initially on non-small cell lung cancer (NSCLC). This initiative expands QIAGEN's existing therascreen KRAS testing portfolio and leverages the company's decade-long expertise in companion diagnostics. QIAGEN holds a strong position in Precision Medicine and has ongoing collaborations with over 25 companies for companion diagnostic tests, indicating a robust pipeline for future product development.

QIAGEN N.V. (NYSE: QGEN) announced the formation of a Scientific Advisory Board to evaluate market and technology trends affecting its growth in Life Sciences and Molecular Diagnostics. The Board features industry leaders such as Dr. Peter Kaspar and Prof. Patrice Nordmann, chaired by Prof. Dr. Ross L. Levine. Additionally, QIAGEN will hold a virtual Annual General Meeting on June 29, 2021, addressing sustainability within an ESG framework and proposing re-elections for seven Supervisory Board members, alongside CEO Thierry Bernard and CFO Roland Sackers.

QIAGEN N.V. has received Emergency Use Authorization (EUA) from the FDA for its QIAreach^® Anti-SARS-CoV-2 Total Test. This portable antibody testing device delivers results in about 10 minutes and can process up to 32 tests per hour using a digital eHub. The test has a sensitivity of 93.85% and a specificity of 97.83%. Developed with Ellume, this test aims to aid in monitoring immunity against COVID-19. QIAGEN also launched the QuantiFERON SARS-CoV-2 test for detecting T-cell responses. The new device enhances the efficiency of serological testing in healthcare settings.

QIAGEN N.V. (NYSE: QGEN) reported a 52% increase in net sales for Q1 2021, reaching $567.2 million. This surpassed the forecast of at least 45% growth. Adjusted earnings per share rose 94% to $0.66, exceeding the expected range of $0.60-0.62. The company's strong performance was attributed to a 16% growth in non-COVID product sales, making up 64% of total sales. QIAGEN also expanded its non-COVID portfolio and is positioned for sustainable growth beyond the pandemic.

QIAGEN N.V. (NYSE: QGEN) is set to launch the EZ2 Connect product line, an advanced automated sample-processing platform designed for biomedical research, forensics, and clinical diagnostics. Utilizing pre-filled cartridges and magnetic bead technology, it processes up to 24 samples in 20 minutes. The platform expands upon the successful EZ1 series, with applications in clinical diagnostics and forensics, and plans to introduce the EZ2 Connect MDx for molecular diagnostics in early 2022. The platform enhances lab automation, safety, and efficiency, backed by significant previous product installations.

QIAGEN and DiaSorin announced the launch of the LIAISON® LymeDetect® Assay, enhancing early detection of Lyme Borreliosis. This assay integrates antibody detection with a unique interferon-gamma release test, achieving a sensitivity of 74% within 21 days, significantly higher than the 49% of existing methods. With a specificity of 100%, it aims to address the critical diagnostic gap and may reduce healthcare costs through earlier treatment. The collaboration leverages both companies' strengths, with DiaSorin managing commercialization while they co-develop the product.

QIAGEN (NYSE: QGEN) has launched the artus® SARS-CoV-2 Prep&Amp UM Kit, enhancing COVID-19 testing efficiency through liquid-based sample preparation. This kit, now CE-IVD registered in the EU and under EUA review by the FDA, supports up to 672 samples in eight hours, reducing waste and time compared to standard methods. QIAGEN aims to increase testing capacity amidst ongoing COVID-19 cases, showcasing a versatile technology applicable beyond the pandemic. The company continues to expand its comprehensive SARS-CoV-2 testing solutions.